Myocardial Fibrosis - Pipeline Review, H2 2017

The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional market research reports and company analyses for over 7 years. Our experienced staff team are on hand to help with any research enquiries you may have, and help you find the right report for your needs. We sell reports to businesses of all sizes across the world who need current market data to plan and develop their business strategies.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1305 753769 or Email: office@sectorpublishing.com
Myocardial Fibrosis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and
enlists all their major and minor projects.

- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D
strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to
gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis
(Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline
therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular)
pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what
drove them from pipeline.

Additional Details

Publisher : Global Markets Direct
Reference : GMDHC99551DB
Number of Pages : 85
Report Format : PDF
Publisher Information : 

© Sector Publishing Intelligence
Limited - 2019

https://www.businessresearchstore.com/product/750234
office@sectorpublishing.com to order
# Table Of Contents for Myocardial Fibrosis - Pipeline Review, H2 2017

- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Myocardial Fibrosis - Overview
- Myocardial Fibrosis - Therapeutics Development
- Pipeline
- Myocardial Fibrosis - Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myocardial Fibrosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myocardial Fibrosis - Companies Involved in Therapeutics Development
- Daewoong Pharmaceutical Co Ltd
- Evotec AG
- Galectin Therapeutics Inc
- Invivosciences Inc
- Lead Discovery Center GmbH
- MandalMed Inc
- Merck & Co Inc
- Miragen Therapeutics Inc
- Palatin Technologies Inc
- ProMetic Life Sciences Inc
- Sarfez Pharmaceuticals Inc
- TRACON Pharmaceuticals Inc
- Myocardial Fibrosis - Drug Profiles
- BMP-7 - Drug Profile
- Carotuximab - Drug Profile
- Drugs for Tissue Fibrosis - Drug Profile
- DWN-10290 - Drug Profile
- GRMD-02 - Drug Profile
- Marinobufagenin for Cardiovascular Diseases - Drug Profile
- MRG-201 - Drug Profile
- NM-922 - Drug Profile
- PBI-4050 - Drug Profile
- PL-5028 - Drug Profile
- PN1-Ab - Drug Profile
- Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
- Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
- Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
- TPI-2049 - Drug Profile
- VB-0004 - Drug Profile
- Myocardial Fibrosis - Dormant Projects
- Myocardial Fibrosis - Product Development Milestones
- Featured News & Press Releases
- Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
- Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
- Appendix
- Methodology
- Disclaimer
How to Buy...

Myocardial Fibrosis - Pipeline Review, H2 2017

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.businessresearchstore.com/product/750234

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at office@sectorpublishing.com or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ________________________________________________________________
Job Title: ________________________________________________________________
Your Email: ________________________________________________________________
Your Contact Phone: _______________________________________________________
Company Name: __________________________________________________________
Address: _________________________________________________________________
Post/Zip Code: ____________________________________________________________
Country: _________________________________________________________________
P.O. Number: _____________________________________________________________
Any Other Instructions: ____________________________________________________

Pricing Options: (please tick one)
- $2000 | Single User Price
- $4000 | Site License Price
- $6000 | Enterprise License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ______________________________________________________

Option 3 - Phone Us on +44 (0)1305 753769
We will be delighted to give you our personal attention.